Advancing a selective oral NMDA receptor modulator toward Phase 2a in chemotherapy-induced peripheral neuropathy following favorable Phase 1 safety and tolerability findings MIAMI, FLORIDA / ACCESS ...
No clinically significant dissociative effects observed in preclinical and Phase 1 assessments to date Not a P-glycoprotein substrate, supporting good oral bioavailability and central nervous system ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results